Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study

{ 'indexed': { 'date-parts': [[2023, 10, 25]], 'date-time': '2023-10-25T05:53:09Z', 'timestamp': 1698213189692}, 'reference-count': 34, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T00:00:00Z', 'timestamp': 1640995200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 5, 13]], 'date-time': '2022-05-13T00:00:00Z', 'timestamp': 1652400000000}, 'content-version': 'vor', 'delay-in-days': 132, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [{'DOI': '10.13039/100018592', 'name': 'Celltrion', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.com.au', 'clinicalkey.es', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022]]}, 'DOI': '10.1016/j.curtheres.2022.100675', 'type': 'journal-article', 'created': {'date-parts': [[2022, 5, 16]], 'date-time': '2022-05-16T22:25:09Z', 'timestamp': 1652739909000}, 'page': '100675', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective ' 'Cohort Study', 'prefix': '10.1016', 'volume': '96', 'author': [ {'given': 'Young Rock', 'family': 'Jang', 'sequence': 'first', 'affiliation': []}, {'given': 'Yoon Ju', 'family': 'Oh', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4306-1597', 'authenticated-orcid': False, 'given': 'Jin Yong', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.curtheres.2022.100675_bib0001', 'unstructured': 'World Health Organization. WHO coronavirus disease (COVID-19) dashboard; ' '2021. Available from: https://covid19.who.int/. Accessed November 15, ' '2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '1023', 'DOI': '10.1016/S0140-6736(21)00306-8', 'article-title': 'Challenges in ensuring global access to COVID-19 vaccines: production, ' 'affordability, allocation, and deployment', 'volume': '397', 'author': 'Wouters', 'year': '2021', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0003', 'doi-asserted-by': 'crossref', 'first-page': 'n1109', 'DOI': '10.1136/bmj.n1109', 'article-title': 'Where are we with drug treatments for covid-19?', 'volume': '373', 'author': 'Baraniuk', 'year': '2021', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0004', 'doi-asserted-by': 'crossref', 'first-page': 'e63', 'DOI': '10.1016/S2213-2600(21)00270-8', 'article-title': 'Repurposing drugs for treatment of COVID-19', 'volume': '9', 'author': 'Venkatesan', 'year': '2021', 'journal-title': 'Lancet Respir Med'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '1469', 'DOI': '10.1056/NEJMp1802256', 'article-title': 'Monoclonal antibodies for emerging infectious diseases - borrowing from ' 'history', 'volume': '378', 'author': 'Marston', 'year': '2018', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '3086', 'DOI': '10.1016/j.cell.2021.05.005', 'article-title': 'Tackling COVID-19 with neutralizing monoclonal antibodies', 'volume': '184', 'author': 'Corti', 'year': '2021', 'journal-title': 'Cell'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0007', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fmed.2020.567296', 'article-title': 'Patterns of deterioration in moderate patients with COVID-19 from Jan ' '2020 to Mar 2020: a multi-center, retrospective cohort study in China', 'volume': '7', 'author': 'Chen', 'year': '2020', 'journal-title': 'Front Med'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '632', 'DOI': '10.1001/jama.2021.0202', 'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial', 'volume': '325', 'author': 'Gottlieb', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0009', 'doi-asserted-by': 'crossref', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with ' 'Covid-19', 'volume': '384', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '1706', 'DOI': '10.1016/j.clinthera.2021.08.009', 'volume': '43', 'author': 'Kim', 'year': '2021', 'journal-title': 'Clin Ther'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0011', 'unstructured': 'Sandulsecu O. Therapeutic effect of regdanvimab in patients with mild to ' 'moderate COVID-19: day 28 results from a multi-centre, randomised, ' 'controlled pivotal trial. Presented at: 31st European Congress of ' 'Clinical Microbiology and Infectious Diseases (ECCMID); July 9–12, 2021; ' 'Online. Presentation 4650.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0012', 'unstructured': "The Korea Economic Daily. Celltrion's COVID-19 treatment reduces " 'incidence of severity by 70%; 2021. Available from: ' 'https://www.kedglobal.com/newsView/ked202107130018. Accessed September ' '29, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0013', 'doi-asserted-by': 'crossref', 'first-page': '2133', 'DOI': '10.1007/s40265-021-01626-7', 'article-title': 'Regdanvimab: First Approval', 'volume': '81', 'author': 'Syed', 'year': '2021', 'journal-title': 'Drugs'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0014', 'unstructured': 'Agência Nacional de Vigilância Sanitária - Anvisa. Anvisa autoriza uso ' 'emergencial de novo medicamento para Covid-19; 2021. Available from: ' 'https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/anvisa-autoriza-uso-emergencial-de-novo-medicamento-para-covid-19. ' 'Accessed September 6, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0015', 'unstructured': 'European Medicines Agency. COVID-19: EMA recommends authorisation of two ' 'monoclonal antibody medicines 2021. Available from: ' 'https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines. ' 'Accessed November 11, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0016', 'unstructured': 'Australian Government Department of Health Therapeutic Goods ' 'Administration. TGA provisional approval of Celltrion Healthcare ' 'Australia Pty Ltd COVID-19 treatment, regdanvimab (REGKIRONA); 2021. ' 'Available from: ' 'https://www.tga.gov.au/media-release/tga-provisional-approval-celltrion-healthcare-australia-pty-ltd-covid-19-treatment-regdanvimab-regkirona. ' 'Accessed December 13, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0017', 'unstructured': 'Republic of Korea: Korea Disease Control and Prevention Agency. The ' 'current status of COVID-19 treatment (February 4, 2022) [Korean]; 2022. ' 'Available from: ' 'http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6352&board_id=312&contSeq=6352. ' 'Accessed February 14, 2022.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0018', 'doi-asserted-by': 'crossref', 'DOI': '10.1183/13993003.03498-2020', 'article-title': 'Systematic evaluation and external validation of 22 prognostic models ' 'among hospitalised adults with COVID-19: an observational cohort study', 'volume': '56', 'author': 'Gupta', 'year': '2020', 'journal-title': 'Eur Respir J'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0019', 'doi-asserted-by': 'crossref', 'first-page': '21545', 'DOI': '10.1038/s41598-020-78392-1', 'article-title': 'Vital signs assessed in initial clinical encounters predict COVID-19 ' 'mortality in an NYC hospital system', 'volume': '10', 'author': 'Rechtman', 'year': '2020', 'journal-title': 'Sci Rep'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0020', 'unstructured': 'Republic of Korea: Central Disaster Management Headquarters and Central ' 'Disease Control Headquarters. Coronavirus disease-19: patient treatment ' 'and management; 2021. Available from: ' 'http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=112&dataGubun=&ncvContSeq=&contSeq=&board_id=&gubun=. ' 'Accessed October 1, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0021', 'unstructured': 'World Health Organization. Living guidance for clinical management of ' 'COVID-19. November 23, 2021; 2021. Available from: ' 'https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. ' 'Accessed February 04, 2022.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0022', 'unstructured': 'Korea Legislation Research Institute, Korean Law Translation Center. ' 'Statutes of the Republic of Korea, Bioethics and Safety Act; 2014. ' 'Available from: ' 'https://elaw.klri.re.kr/eng_mobile/viewer.do?hseq=33442&type=part&key=36. ' 'Accessed June 11, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0023', 'unstructured': 'National Institutes of Health. Coronavirus disease 2019 (COVID-19) ' 'treatment guidelines; 2021. Available from: ' 'https://www.covid19treatmentguidelines.nih.gov/. Accessed June 14, ' '2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0024', 'doi-asserted-by': 'crossref', 'first-page': '233', 'DOI': '10.1016/j.ijid.2020.10.067', 'article-title': 'Asymptomatic hypoxia in COVID-19 is associated with poor outcome', 'volume': '102', 'author': 'Brouqui', 'year': '2021', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '2451', 'DOI': '10.1056/NEJMcp2009575', 'article-title': 'Severe Covid-19', 'volume': '383', 'author': 'Berlin', 'year': '2020', 'journal-title': 'N Engl J Med.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0026', 'unstructured': 'World Health Organization. Interim guidance for member states - on the ' 'use of pulse oximetry in monitoring Covid-19 patients under home-based ' 'isolation and care 2021. Available from: ' 'https://www.afro.who.int/sites/default/files/Covid-19/Techinical%20documents/GUIDELINES%20FOR%20THE%20USE%20OF%20PULSE%20OXIMETRY%20IN%20MONITORING%20COVID-19%20PATIENTS%20IN%20HBIC.pdf. ' 'Accessed September 29, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0027', 'doi-asserted-by': 'crossref', 'first-page': '264', 'DOI': '10.3389/fpubh.2020.00264', 'article-title': 'The clinical characteristics and prognosis factors of mild-moderate ' 'patients with COVID-19 in a mobile cabin hospital: a retrospective, ' 'single-center study', 'volume': '8', 'author': 'Zhang', 'year': '2020', 'journal-title': 'Front Public Health'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0028', 'doi-asserted-by': 'crossref', 'first-page': '6483', 'DOI': '10.1038/s41598-021-85869-0', 'article-title': 'Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a ' 'retrospective cohort study', 'volume': '11', 'author': 'Zhai', 'year': '2021', 'journal-title': 'Sci Rep'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0029', 'first-page': 'e14933', 'article-title': 'Clinical impact of the early use of monoclonal antibody LY-CoV555 ' '(bamlanivimab) on mortality and hospitalization among elderly nursing ' 'home patients: a multicenter retrospective study', 'volume': '13', 'author': 'Alam', 'year': '2021', 'journal-title': 'Cureus'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '24', 'DOI': '10.1093/cid/ciab305', 'article-title': 'Real-world experience of bamlanivimab for COVID-19: a case-control ' 'study', 'volume': '74', 'author': 'Kumar', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0031', 'doi-asserted-by': 'crossref', 'DOI': '10.1177/21501327211019282', 'article-title': 'Influence of social and cultural factors on the decision to consent for ' 'monoclonal antibody treatment among high-risk patients with ' 'mild-moderate COVID-19', 'volume': '12', 'author': 'Bierle', 'year': '2021', 'journal-title': 'J Prim Care Community Health'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0032', 'unstructured': 'European Medicines Agency. Regdanvimab assessment report; 2021. ' 'Available from: ' 'https://www.ema.europa.eu/en/documents/referral/regdanvimab-treatment-covid-19-celltrion-covid-19-article-53-procedure-assessment-report_en.pdf. ' 'Accessed September 30, 2021.'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0033', 'doi-asserted-by': 'crossref', 'first-page': '135', 'DOI': '10.1016/j.bbrc.2021.06.016', 'article-title': 'Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant', 'volume': '566', 'author': 'Ryu', 'year': '2021', 'journal-title': 'Biochem Biophys Res Commun'}, { 'key': '10.1016/j.curtheres.2022.100675_bib0034', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1016/j.bbrc.2021.09.023', 'article-title': 'The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and ' 'its associated variants of SARS-CoV-2', 'volume': '578', 'author': 'Ryu', 'year': '2021', 'journal-title': 'Biochem Biophys Res Commun'}], 'container-title': 'Current Therapeutic Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0011393X22000145?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0011393X22000145?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 1, 13]], 'date-time': '2023-01-13T06:48:04Z', 'timestamp': 1673592484000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0011393X22000145'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022]]}, 'references-count': 34, 'alternative-id': ['S0011393X22000145'], 'URL': 'http://dx.doi.org/10.1016/j.curtheres.2022.100675', 'relation': {}, 'ISSN': ['0011-393X'], 'subject': ['Pharmacology (medical)', 'Pharmacology'], 'container-title-short': 'Current Therapeutic Research', 'published': {'date-parts': [[2022]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: ' 'A Retrospective Cohort Study', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Current Therapeutic Research', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.curtheres.2022.100675', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 The Authors. Published by Elsevier Inc.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '100675'}